Correlation of hematological indexes and expression of HER-2 in patients with breast cancer

doi:10.3969/j.issn.1673-8640.2022.06.003

Abstract

Abstract:

Objective To investigate the correlation of hematological indexes and expression of human epidermal growth factor receptor-2（HER-2） in patients with breast cancer. Methods Totally,133 patients with invasive breast cancer were enrolled,and they were classified into HER-2 positive group（41 cases） and HER-2 negative group（92 cases）. The clinical characteristics and hematological indexes were compared between the 2 groups. Results Compared with HER-2 negative group,HER-2 positive group had a higher red cell volume distribution width（RDW） and a lower platelet distribution width（PDW）（P<0.05）. The optimal cut-off values of RDW and PDW for the differential diagnosis of HER-2 expression were 13.35% and 49.70 fL,respectively. The expression of HER-2 was correlated with lymph node metastasis（P<0.05）. A high level of RDW（≥13.35%） and a low level of PDW（<49.70 fL） were correlated with HER-2 expression in breast cancer tissues（P<0.05）. Conclusions RDW and PDW are correlated with HER-2 expression in breast cancer tissues,and they provide a reference for the differential diagnosis of benign and malignant breast cancer.

Key words: Breast cancer, Human epidermal growth factor receptor-2, Red cell volume distribution width, Platelet distribution width

CLC Number:

R446.1

YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer[J]. Laboratory Medicine, 2022, 37(6): 514-517.

Figures/Tables 4

References 14

[1]	SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics,2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2]	DESANTIS C E, MA J, GAUDET M M, et al. Breast cancer statistics,2019[J]. CA Cancer J Clin, 2019, 69(6):438-451.
[3]	ELINAV E, NOWARSKI R, THAISS C A, et al. Inflammation-induced cancer:crosstalk between tumors,immune cells and microorganisms[J]. Nat Rev Cancer, 2013, 13(11):759-771.
[4]	郭奕阳, 邓艳丽, 郭秀娟, 等. 乳腺癌患者HER-2胞外结构域的临床价值[J]. 检验医学, 2017, 32(10):871-874.
[5]	赵卫卫, 肖林林, 刘秀芬, 等. 术前外周血中性粒细胞/淋巴细胞比值在乳腺癌诊断中的作用[J]. 检验医学, 2018, 33(3):209-212.
[6]	OKTAY K, SANTALIZ-CASIANO A, PATEL M, et al. A computational statistics approach to evaluate blood biomarkers for breast cancer risk stratification[J]. Horm Cancer, 2020, 11(1):17-33.
[7]	陈力, 孔祥溢, 方仪, 等. 外周血中常见血液学参数对乳腺癌预后评估价值的研究进展[J]. 现代生物医学进展, 2019, 19(23):4582-4585.
[8]	钟田花, 王文强, 陈振辉, 等. 乳腺癌患者血小板/淋巴细胞比值及红细胞分布宽度检测的临床价值[J]. 海南医学, 2018, 29(16):2284-2287.
[9]	YAO D, WANG Z, CAI H, et al. Relationship between red cell distribution width and prognosis in patients with breast cancer after operation:a retrospective cohort study[J]. Biosci Rep, 2019, 39(7):BSR20190740.
[10]	SERETIS C, SERETIS F, LAGOUDIANAKIS E, et al. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study[J]. J Clin Med Res, 2013, 5(2):121-126.
[11]	TAKEUCHI H, ABE M, TAKUMI Y, et al. Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer[J]. Sci Rep, 2019, 9(1):3033.
[12]	TAKEUCHI H, ABE M, TAKUMI Y, et al. The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer[J]. PLoS One, 2017, 12(12):e0189166.
[13]	SAKIN A, SAHIN S, SAKIN A, et al. Mean platelet volume and platelet distribution width correlates with prognosis of early colon cancer[J]. J BUON, 2020, 25(1):227-239.
[14]	YUE C X, LIU Y X, YUN Z Y, et al. Decreased platelet distribution width predicts a worse prognosis in patients undergoing surgical resection for hepatocellular carcinoma[J]. Cancer Biomark, 2019, 26(3):361-366.

临床病理特征	例数	HER-2阴性（92例）	HER-2阳性（41例）
年龄
≤50岁	91	65	26
>50 岁	42	27	15
χ²值		0.688
P值		0.407
绝经状态
未绝经	90	65	25
已绝经	43	27	16
χ²值		1.214
P值		0.271
TNM分期
Ⅰ期	54	41	13
Ⅱ期	50	30	20
Ⅲ期	28	20	8
Ⅳ期	1	1	0
χ²值		3.640
P值		0.303
WHO分级
Ⅰ级	22	17	5
Ⅱ级	97	65	32
Ⅲ级	14	10	4
χ²值		0.923
P值		0.630
淋巴结转移
无转移	76	58	18
有转移	57	34	23
χ²值		4.243
P值		0.039

临床病理特征	例数	HER-2阴性（92例）	HER-2阳性（41例）
年龄
≤50岁	91	65	26
>50 岁	42	27	15
χ²值		0.688
P值		0.407
绝经状态
未绝经	90	65	25
已绝经	43	27	16
χ²值		1.214
P值		0.271
TNM分期
Ⅰ期	54	41	13
Ⅱ期	50	30	20
Ⅲ期	28	20	8
Ⅳ期	1	1	0
χ²值		3.640
P值		0.303
WHO分级
Ⅰ级	22	17	5
Ⅱ级	97	65	32
Ⅲ级	14	10	4
χ²值		0.923
P值		0.630
淋巴结转移
无转移	76	58	18
有转移	57	34	23
χ²值		4.243
P值		0.039

组别	例数	RDW/%		PDW/fL
组别	例数	<13.35	≥13.35	<49.70	≥49.70
HER-2阴性组	92	54	38	23	69
HER-2阳性组	41	13	28	19	22
χ²值		8.263		5.978
P值		0.004		0.015

组别	例数	RDW/%		PDW/fL
组别	例数	<13.35	≥13.35	<49.70	≥49.70
HER-2阴性组	92	54	38	23	69
HER-2阳性组	41	13	28	19	22
χ²值		8.263		5.978
P值		0.004		0.015

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578.
[3]	ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429.
[4]	LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239.
[5]	LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147.
[6]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[7]	WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820.
[8]	CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341.
[9]	YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348.
[10]	ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40.
[11]	MAO Zheng, QIAN Zengkun, YING Fei, WANG Zhaoli, XIAO Qun, CUI Fan. Correlation between E-Cad,G-17,HER-2 and postoperative recurrence risk of gastric cancer [J]. Laboratory Medicine, 2022, 37(1): 41-46.
[12]	LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718.
[13]	YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329.
[14]	LIU Xiufen, AO Hongfeng, AO Jinping. Expression of programmed cell death 5 in breast cancer and its clinical value [J]. Laboratory Medicine, 2021, 36(11): 1151-1158.
[15]	JIN Shu, ZHU Qi, ZHU Yuan, YUAN Ya, CAI Xiaoyao, ZHANG Ji, YAN Peiyi. Methylation level and mRNA expression of CpG island of HER2 gene in breast cancer and its adjacent tissues [J]. Laboratory Medicine, 2020, 35(5): 481-486.